Viatris' Biosimilars

Biocon Biologics to Acquire Viatris' Biosimilars Assets for USD 3.335 Billion

Biocon Biologics Ltd (BBL) will acquire Viatris' biosimilars business to create a unique fully integrated global biosimilars enterprise.